LONDON (dpa-AFX) - Anglo-Swedish drug maker AstraZeneca Plc. (AZN, AZN.L) and Bristol-Myers Squibb Co. (BMY) announced top-line results of the Phase IV SAVOR-TIMI-53, or Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus, clinical trial of Onglyza or saxagliptin.
According to the companies, in this study of adult patients with type 2 diabetes with either a history of established cardiovascular disease or multiple risk factors, Onglyza met the primary safety objective of non inferiority, and did not meet the primary efficacy objective of superiority, for a composite endpoint of cardiovascular death, non-fatal myocardial infarction or non-fatal ischaemic stroke, when added to a patient's current standard of care (with or without other anti-diabetic therapies), as compared to placebo.
Onglyza is indicated as an adjunct to diet and exercise to improve glycemic (blood sugar) control in adults with type 2 diabetes mellitus in multiple clinical settings. Onglyza should not be used for the treatment of patients with type 1 diabetes mellitus or diabetic ketoacidosis (increased levels of ketones in the blood or urine), as it would not be effective in these settings. Onglyza has not been studied in patients with a history of pancreatitis.
AstraZeneca and Bristol-Myers Squibb are working in collaboration to research, develop and commercialize a versatile portfolio of innovative treatment options for diabetes and related metabolic disorders that aim to provide treatment effects beyond glucose control.
Copyright RTT News/dpa-AFX